{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:35:47Z","timestamp":1773131747652,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clinthera.2018.08.016","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:48:35Z","timestamp":1537318115000},"page":"1720-1728.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-0837","authenticated-orcid":false,"given":"Su-jin","family":"Rhee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.08.016_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.05.005","article-title":"Diabetic neuropathy: mechanisms to management","volume":"120","author":"Edwards","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2018.08.016_bib0002","first-page":"144","article-title":"Quality of life and its relationship to the degree of illness acceptance in patients with diabetes and peripheral diabetic neuropathy","volume":"52","author":"Lewko","year":"2007","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5455\/jeim.031113.hp.009","article-title":"An option for painful diabetic neuropathy with simultaneous 'antioxidative' and 'anesthetic' properties: topical Citrullus colocynthis","volume":"4","author":"Heydari","year":"2014","journal-title":"J Exp Integr Med"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2018.08.016_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pmrj.2011.03.008","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"3","author":"Bril","year":"2011","journal-title":"PMR"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0006","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/dc07-2105","article-title":"Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses","volume":"31","author":"Freeman","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/dmr.5610110303","article-title":"The role of oxidative stress in neuropathy and other diabetic complications","volume":"11","author":"Van Dam","year":"1995","journal-title":"Diabetes Metab Rev"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0008","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0891-5849(99)00011-8","article-title":"Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria","volume":"26","author":"Borcea","year":"1999","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0145721706297450","article-title":"Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy","volume":"33","author":"Foster","year":"2007","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0010","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2018.08.016_bib0011","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/dmrr.817","article-title":"Painful diabetic neuropathy: treatment and future aspects","volume":"24","author":"Ziegler","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0012","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1177\/0091270003258654","article-title":"Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers","volume":"43","author":"Teichert","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0013","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270009352087","article-title":"Clinical pharmacokinetics of pregabalin in healthy volunteers","volume":"50","author":"Bockbrader","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0014","first-page":"1411","article-title":"Pharmacokinetics of the evogliptin\/metformin extended-release (5\/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects","volume":"10","author":"Rhee","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0015","first-page":"413","article-title":"Bioequivalence of thioctic acid HR tablet to Daewon thioctic acid HR tablet 600 mg","volume":"35","author":"Kang","year":"2006","journal-title":"J Kor Pharm Sci (in Korean)"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0016","series-title":"Guidance on Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products\u2014General Considerations","year":"2003"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/0091270004270792","article-title":"Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease","volume":"45","author":"Teichert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0018","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0091270003251119","article-title":"Pharmacokinetics of pregabalin in subjects with various degrees of renal function","volume":"43","author":"Randinitis","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0019","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2007.01.013","article-title":"Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders","volume":"29","author":"Tassone","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0021","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1528-1167.2005.19204.x","article-title":"Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1528-1167.2010.02763.x","article-title":"Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine","volume":"52","author":"Bockbrader","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1046\/j.1365-2125.1999.00097.x","article-title":"Lack of interaction between thioctic acid, glibenclamide and acarbose","volume":"48","author":"Gleiter","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0024","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jps.2600821125","article-title":"Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies","volume":"82","author":"Blume","year":"1993","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0928-0987(98)00061-X","article-title":"Dose-proportionality of oral thioctic acid\u2014coincidence of assessments via pooled plasma and individual data","volume":"8","author":"Breithaupt-Gr\u00f6gler","year":"1999","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0026","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1212\/NXI.0000000000000380","article-title":"Lipoic acid pharmacokinetics at baseline and 1 year in secondary progressive MS","volume":"4","author":"Bittner","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.clinthera.2018.08.016_bib0027","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11095-008-9681-5","article-title":"Investigation of the drug-drug interaction between alpha-lipoic acid and valproate via mitochondrial beta-oxidation","volume":"25","author":"Phua","year":"2008","journal-title":"Pharm Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:38:26Z","timestamp":1720618706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818303795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0149291818303795"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}